Table 1.

Summary of lymphocyte proliferative responses as group mean stimulation indices as measured by ³H-thymidine incorporation in PBMC from semi-immune Malian adults receiving either the three-dose series of FMP2.1/AS02A (half (25µg/0.25 ml) or full (50µg/0.5 ml) dose) or the comparator RabAvert® vaccine.

Cohort	Vaccine (n)	Stimulation index Day 0a	Stimulation index Day 90	P valueb(study vs. control)	P value (Day 0 vs. Day 90)
1	Half-dose FMP2.1/AS02A (18)	2.38	5.19		nsc
	RabAvert® (10)	2.00	1.08	0.005	ns
2	Full dose FMP2.1/AS02A (18)	1.15	6.53		0.002
	RabAvert® (9)	1.19	1.88	0.004	ns
Combined	FMP2.1/AS02A (36)	1.65	5.84		0.002
	RabAvert® (19)	1.59	1.41	<0.0001	ns

(n) = (number of volunteers).

^aNo statistical difference of stimulation indices noted between cohorts at Day 0, pre-vaccination.

^bStatistical analysis performed on Day 90 FMP2.1 vaccine vs. RabAvert® comparator vaccine with level of significance defined as P < 0.05.

^cNot statistically significant (ns).